This article is more than 5 years old. Information may no longer be current.

Glaucoma to account for half of market revenues in future

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The worldwide ophthalmic disease therapeutics market is expected to reach $3.65 billion in 2004 and increase steadily over the next 5 years, according to a market research report. Glaucoma will continue to be the most medically treated indication, the report states.

The ophthalmic disease therapeutics market will continue its growth at a compound annual rate of 11.9% to reach about $6.41 billion worldwide in 2009, according to Research and Markets: Emerging Ophthalmic Therapeutics. Glaucoma will account for 50% of the market revenues, according to the report, “but the emergence of therapies to treat age-related macular degeneration and other retinal neovascular conditions will contribute substantially to market growth.”

Companies profiled in the report include Alcon, Allergan, AstraZeneca, Bausch & Lomb, Cambridge Antibody Technology, Control Delivery Systems, Eyetech Pharmaceuticals, Genzyme, Gilead Sciences, Ista Pharmaceuticals, Merck & Co., Miravant Medical Technologies, Novartis, Pfizer and Santen.